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729Abstracts
sufferers. The magnitude of the quality of life improve-
ments estimated in this study allows therapies, which
reduce the burden of GI toxicities to be evaluated in a
cost-utility framework.
OSTEOPOROSIS—Cost Studies
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OBJECTIVE: To develop an epidemiological model of
osteoporosis and its sequelae to estimate the current and
future prevalence and costs of osteoporotic fractures 
to the NHS. METHODS: A decision-analytic model
employing a Markov process was constructed using MS
Excel. The model incorporates key epidemiological data
and modelled treatment pathways with published cost
data of fracture/osteoporosis treatment. The model esti-
mates the current population of post-menopausal women,
using prevalence data from the European Vertebral
Osteoporosis Study (EVOS), along with current usage of
anti-fracture medication. The rate of incident fractures
from the European Prospective Osteoporosis Study
(EPOS) is modiﬁed by the increased risk of subsequent
fracture and the protection gained with treatment. Costs
were based on Dolan & Torgerson (1998): Hip frac-
ture £16,000 (1st year of fracture); vertebral fracture
£321–£3,543; wrist fracture £394; other fracture £1,138.
RESULTS: The model estimates almost 345,000 fractures
will occur in 2003, resulting in costs of over £800 million.
Vertebral fractures are the most common type, with an
estimated 177,000 fractures in 2003 at a cost of £72
million. Hip fractures account for approximately 83% of
the total costs, with an estimated 40,000 fractures costing
£634 million. Around 65,000 wrist fractures are esti-
mated, at a cost of approximately £25 million, with a
further 61,000 “other” fractures costing around £70
million. This model does not currently include males, and
hence these results underestimate the true cost of osteo-
porosis to the NHS. CONCLUSIONS: The costs of osteo-
porosis fractures are substantial. This results from a high
incidence of fractures and expensive health care (primar-
ily secondary care). Vertebral fractures are over four times
as common as hip fractures, which indicates a substan-
tial health burden, although hip fractures are more costly.
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OBJECTIVE: To develop an epidemiological model of
osteoporosis and its sequelae to estimate the current and
future prevalence of osteoporotic fractures in females
aged 45 years and over, in different European countries.
METHODS: A decision-analytic model employing a
Markov process was constructed using MS Excel.
Country-speciﬁc population projection ﬁgures were com-
bined with data from major European epidemiological
studies to estimate the current and future prevalence of
osteoporotic fractures in women. Regional prevalence
data came from the European Vertebral Osteoporosis
Study (EVOS) and incidence data from the follow-up
European Prospective Osteoporosis Study (EPOS).
Results for France, Germany (Western Europe), Italy,
Spain (Southern Europe), Sweden, and Finland (Scandi-
navia) will be presented. RESULTS: A total of 1.8 million
osteoporotic fractures are estimated to occur in women
aged 45 years and older in these 6 countries in 2003. Ver-
tebral fractures are the most common type, accounting
for almost 1.1 million of all fractures. It is also estimated
there will be almost 250,000 wrist fractures, 220,000hip
fractures and 290,000 “other” fractures. The overall rates
of fractures are substantially higher for the Scandinavian
countries than for the other countries: France 28.2/1000,
Germany 28.4/1000, Italy 28.8/1000, Spain 31.0/1000,
Finland 61.9/1000, and Sweden 71.0/1000 women.
CONCLUSIONS: Osteoporotic fractures are an impor-
tant cause of morbidity in these countries. Vertebral frac-
tures are the most common type, thus warranting study
of their economic and health impact. The variations in
rate of fracture between regions reﬂect predominantly 
the differing prevalence and incidence rates found in the
EVOS and EPOS studies, and to a lesser extent, the
country-speciﬁc age structures.
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OBJECTIVES: To estimate the hospitalisation costs of
accidental injuries in the European Union (EU) resulting
from the use of benzodiazepines. METHODS: Design: A
case-control study on the association between accidental
falls and benzodiazepines. Setting: Community–dwelling
inhabitants over 55 years of deﬁned areas in The Nether-
lands covering the period 1985–2000. All analyses were
performed from the perspective of a third-party payer.
Studies: Risk and exposure data were obtained from the
Dutch PHARMO system, a population-based register of
drug-dispensing records and hospital records. The popu-
lation attributable risk (PAR) was calculated with the age
speciﬁc prevalence estimates of benzodiazepine use and
the corresponding odds ratios (OR) obtained from a case
